Policy and perspectives

Nick Stringfellow, explores the key considerations that manufacturers should be aware of and the future lessons that will come following publication of the first JCAs.

Adam Ben Taieb explores why turning new healthcare innovations into accessible patient treatments requires more than scientific excellence - it demands strategic navigation of an increasingly complex market access landscape.

Ethan Shum presents explores how six HTA bodies address carer quality of life.

Marietta Paraskevaidou explores HTA representatives’ perspectives on patient involvement in EU-level health technology assessments.

Amina Igenbek presents research at ISPOR Europe 2025 examining how ten low- and middle-income countries enable access to unregistered medicines.

Dr Bhakti Dhingra explores how subscription-style agreements are being applied in real-world settings, the benefits and challenges they bring and what the future may hold for this approach.

How European HTA agencies are adapting to the introduction of Joint Clinical Assessments (JCA), balancing the promise of greater efficiency and transparency against the realities of implementation.

Dr Bhakti Dhingra breaks down the key features of the new guidance and its implications for manufacturers.

Dr Bhakti Dhingra delves into the key features of the draft regulation and highlights the potential impacts on pharmaceutical companies.

Yasmina Zegaoui takes a look at the new discounted prices for selected drugs for 2026.